Our previous work demonstrated that the E7-specific fusion protein vaccine PE-E7-K3 (PEK) was able to enhance the E7-specific immunity of both CD4 and CD8 T cells by targeting the HPV-16 E7 oncoprotein, generating potent E7-specific anti-tumor effects against impalpable pulmonary tumor nodules [20]. This evidence concerns the gene CD8A and neoplasm.